LTX-401
/ Lytix
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 12, 2026
Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report
(Lytix Biopharma Press Release)
- "The ATLAS-IT-05 Phase II study in advanced melanoma was completed, with preparation of the clinical study report ongoing and expected to be finalized in the first quarter of 2026; Evaluating all strategic opportunities to accelerate the development of LTX-401."
Clinical • Trial status • Hepatocellular Cancer • Melanoma
February 13, 2025
Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025
(Lytix Biopharma Press Release)
- "LTX-401: New superior formulation with enhanced anticancer effects and extended patent life; clinical trials planned for 2026."
New trial • Oncology
1 to 2
Of
2
Go to page
1